Astex Pharma
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
US FDA approves Taiho’s Inqovi for older adults with acute myeloid leukaemia
In 2026, an estimated 22,720 people in the US will be diagnosed with AML
MSD receives NICE recommendation for Keytruda in advanced endometrial cancer
More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK
Merck unveils $3bn cost-cutting plan to support pipeline and new product launches
A new restructuring programme has been approved to support the initiative
MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive
Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO
Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn
Cardiovascular diseases result in an estimated 17.9 million global deaths each year
MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease
Approximately one in every 70,000 people are affected by the tumour-causing genetic disease
MSD and Astex announce expansion to oncology drug discovery collaboration
Astex will receive $35m upfront plus milestone payments totalling $500m per programme
MSD and Eisai’s combination therapy recommended by NICE for advanced endometrial cancer
More than 9,700 people are diagnosed with womb cancer each year in the UK
MSD’s Keytruda to be made available in England for advanced cervical cancer patients
Around 2,600 people are diagnosed with cervical cancer each year in England
AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
More than 52,000 men are diagnosed with prostate cancer every year in the UK alone